India’s Biomedical Research Architecture Is Being Rebuilt

The Question Is Whether the Ambition Can Outlast the Bureaucracy

A ₹10,000-crore biopharma scheme, a 24% budget surge, 1,000 new clinical trial sites, and a novel metric system for measuring scientific impact — ICMR is in the middle of its most sweeping structural overhaul in a generation. The design is coherent. The execution is the test, Rashmi Kumari of Neo Science Hub, reports.  

Something significant has shifted in the institutional posture of Indian biomedical research. The shift is not sudden — it has been accumulating in policy documents, budget allocations, and platform launches over the past three years — but in the months since the Union Budget 2026–27, it has become visible enough to demand examination. India, the country that supplies one-fifth of the world’s generic medicines, is attempting to graduate from being a competent imitator of other nations’ pharmaceutical discoveries to becoming a sovereign generator of its own. The institutional vehicle for that ambition, at least on the health research side, is the Indian Council of Medical Research. And the ambition is now backed, for the first time, by resources and structural commitments that are proportionate to its scale.

The numbers are not trivial. The allocation for the Department of Health Research in 2026–27 has risen from Rs. 3,900 crore to over Rs. 4,820 crore — a 24 per cent increase in a single financial year. The flagship Biopharma SHAKTI scheme — Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation — carries an outlay of Rs. 10,000 crore over five years. Under SHAKTI, a nationally accredited network of over 1,000 clinical trial sites is to be established under ICMR, three new NIIPERs are to be created, seven existing ones upgraded, and CDSCO is to be strengthened with a dedicated scientific review cadre capable of meeting global approval timeframes. These are not incremental adjustments. They are structural bets.

The question that serious science policy observers are now asking is not whether the intent is real. The intent appears real. The question is whether India’s institutional systems — fragmented clinical research infrastructure, a procurement landscape that has historically been slow and specification-inconsistent, a regulatory body in CDSCO that has faced sustained criticism for approval delays, and a funding culture that until recently privileged publication counts over translational impact — can be reformed quickly enough to make the ambition operational within a credible timeframe.

A New Measurement System for Science Itself

Before the money and the schemes, something less visible but arguably more consequential has been happening inside ICMR’s own evaluation architecture. The council has introduced a metric system called ICMR-IRIS — the Impact of Research and Innovation Scale — built around a unit called the Publication Equivalent, or PE. The system is designed to correct a structural distortion that has long characterised Indian biomedical research funding: the overvaluation of publications and the undervaluation of everything that happens after a paper is written.

Under the PE framework, a standard peer-reviewed publication earns one equivalent unit. A highly cited paper earns three. A patent earns five. A developed technology earns ten. A technology that is commercialised and reaches patients at scale earns twenty. The arithmetic is deliberate: it is designed to make translation and impact twenty times more attractive than publication alone, at least in career and project-evaluation terms. The system also reshapes how experts are selected for ICMR’s Scientific Advisory Committees and Project Review Committees — moving from a reputational hierarchy model toward one in which research track records are assessed by objectively verifiable metrics rather than by seniority or institutional affiliation.

The reform has not been universally embraced. Some researchers have argued that the framework may disadvantage fundamental science, which generates the foundational knowledge on which applied innovations depend. The counterargument — advanced by ICMR leadership — is that the PE system does not penalise basic research; it simply gives additional and substantial weight to research that moves further along the bench-to-bedside continuum. That debate reflects a genuine tension in research priority-setting that every major national science agency in the world has struggled with, and India is no exception. What is notable is that ICMR has chosen to resolve it structurally rather than merely rhetorically.

MedTech Mitra and Patent Mitra

Parallel to the metric reforms, ICMR has been building what might be called the connective tissue of an innovation economy — the platforms, processes, and partnerships that allow a laboratory discovery to become a product that reaches a patient. Two initiatives anchor this effort.

MedTech Mitra, a joint initiative of ICMR, NITI Aayog, and CDSCO, functions as a structured handholding platform for Indian med-tech innovators. Its stated purpose is to accelerate the development of regulation-compliant Indian innovations by providing support across clinical evaluation, regulatory navigation, quality standards, calibration requirements, and Government e-Marketplace procurement readiness. Since its launch, the platform has conducted at least seven Experiential Learning Workshops for innovators and startups, with a Knowledge Series session under medical devices as recently as April 17, 2026. An Expression of Interest for batch manufacturing of medical devices and diagnostics for clinical investigation is currently open.

Medical Innovations Patent Mitra, launched in March 2025 with Union Health Minister JP Nadda presiding, addresses the intellectual property gap that has long prevented Indian biomedical research from capturing the economic value it generates. India’s life sciences patent filing rate has been disproportionately low relative to the volume of research its institutions produce — a gap that Patent Mitra is designed to close through end-to-end support covering patentability assessment, filing, prosecution, maintenance, and technology transfer facilitation. At India MedTech Expo 2025 in September, Patent Mitra facilitated 17 technology licensing agreements covering diagnostics for dengue, chikungunya, Japanese encephalitis, and other infectious diseases, as well as candidate vaccines for Shigella and Plasmodium falciparum. An Innovator to Industry Connect conclave was held at Bharat Mandapam in April 2026. The stated target is a tenfold increase in Indian life science patents within two years.

The significance of these platforms lies not in any individual event but in what they collectively signal: ICMR is attempting to build the missing middle of India’s biomedical innovation system — the infrastructure between a discovery and its adoption. That middle has historically been the weakest link. Patents have lapsed. Technologies have stayed in journals. Innovators have lacked the regulatory knowledge to get products through CDSCO. Procurement systems have been slow to absorb indigenously developed products. MedTech Mitra and Patent Mitra are institutional responses to each of these specific failures.

The 1,000 Clinical Trial Sites

Of all the commitments in the Biopharma SHAKTI package, the establishment of a nationally accredited network of over 1,000 clinical trial sites under ICMR is the most consequential and the most operationally challenging. India is ranked fourth in the world for clinical trials by volume. But that ranking masks a structural thinness: the bulk of India’s trial activity is concentrated in a small number of well-resourced urban institutions — AIIMS Delhi, major private hospitals in Mumbai and Chennai, a handful of well-established CROs. The geographic and institutional spread required to make 1,000 sites functional, accredited, and GCP-compliant does not currently exist.

ICMR has been building toward this through predecessor programmes. The Indian Clinical Trial and Education Network, INTENT, currently integrates 75 sites for multicentric Phase II and Phase III trials. The ICMR Phase I Clinical Trial Network, established through a competitive vetting process in 2024, identified four partnering institutions for early-phase studies in oncology, vaccines, and cell and gene therapy — with first trials scheduled for 2025. These are meaningful foundations. But the distance from 75 operational INTENT sites to 1,000 accredited SHAKTI sites is a journey that will require not just capital but institutional capacity-building at medical colleges, district hospitals, and research institutions that have not previously been embedded in a clinical trials ecosystem.

The history here warrants attention. After India tightened its clinical trial regulations in 2013 in response to concerns about compensation for trial-related injuries and simultaneous multi-trial participation, there was a significant decline in trial registrations. The regulatory overcorrection took years to resolve, and the subsequent New Drugs and Clinical Trials Rules of 2019 only partially restored confidence. The ICMR leadership is aware of this history. The current push to build clinical trial capacity — particularly for biologics and biosimilars, where India has minimal indigenous data — is partly an attempt to ensure that the next generation of Indian-developed therapeutics can be validated in India rather than in foreign trial networks that may not prioritise Indian disease populations or Indian cost parameters.

“The allocation for the Department of Health Research has increased from Rs. 3,900 crore to over Rs. 4,820 crore — a 24% increase. The Bio-Pharma Shakti announced in the Budget will be very important in taking forward the dream of Viksit Bharat.”

Dr. Rajiv Bahl, February 2026

What the Ambition Requires That the System Has Not Yet Delivered

The coherence of the vision is not in doubt. The ICMR-IRIS metric system, the MedTech Mitra and Patent Mitra platforms, the Biopharma SHAKTI infrastructure commitment, and the budget increase collectively constitute a recognisable strategic logic: measure science by impact, protect the intellectual property that science generates, build the infrastructure needed to validate it clinically, and fund the ecosystem at a scale commensurate with the ambition. The pieces fit together.

What the architecture requires, and what the system has not yet demonstrated it can reliably deliver, is execution at the institutional periphery. ICMR operates through more than 100 institutes spread across India, many of which have historically operated in relative isolation from the translation infrastructure that Delhi is now trying to build. The ANVESHAN extramural grants programme, which ICMR relaunched in 2026 with a 4Ds framework — Discovery, Development, Delivery, and Descriptive research — provides funding up to Rs. 2 crore for individual investigator projects and up to Rs. 25 crore for large multi-state studies under the National Health Research Programme. Whether those funds translate into projects that feed the MedTech Mitra pipeline rather than simply producing publications depends on incentive structures, mentorship systems, and institutional culture change that cannot be mandated by a budget line.

The procurement dimension is equally critical and equally under-examined. Ambitious clinical trial networks and innovation platforms require research infrastructure that can be procured at consistent quality, at reasonable speed, and in a manner that actively favours indigenous products where those products meet specification. These are the operational challenges that sit between the strategic vision and its implementation — unglamorous, invisible in press releases, but determinative of whether the vision is realised.